<DOC>
	<DOCNO>NCT02204020</DOCNO>
	<brief_summary>Despite improvement outcomes Hematopoietic Cell Transplantation ( HCT ) Acute Myeloid Leukemia ( AML ) Myelodysplastic Syndrome ( MDS ) , risk relapse remain high common cause mortality HCT . Moreover , treatment option relapse HCT limit . Strategies reduce relapse maintenance therapy patient high risk need improve survival . 5-aza hypomethylating agent show immune modulating property may enhance graft-versus-leukemia ( GVL ) effect , include upregulation tumor-associated antigen costimulatory molecule expression . Moreover , 5-aza property suggest protection graft-versus-host disease ( GVHD ) well . Preliminary data show well tolerate effective clinical use treatment AML MDS relapse HCT , well maintenance therapy . This study evaluate use 5-aza maintenance HCT patient AML MDS risk factor associate high risk relapse .</brief_summary>
	<brief_title>Phase II Study 5-azacytidine Maintenance After Transplant AML MDS</brief_title>
	<detailed_description>Phase II study 5-aza maintenance allogeneic Hematopoietic Cell Transplantation ( HCT ) high-risk Acute Myeloid Leukemia ( AML ) Myelodysplastic Syndrome ( MDS ) . Early study indicate 5-aza hypomethylating agent show immune modulating property may enhance graft-versus-leukemia ( GVL ) effect , include upregulation tumor-associated antigen costimulatory molecule expression . 5-aza also property suggest protection graft-versus-host disease ( GVHD ) . The primary objective evaluate relapse rate one year . Secondary objective include incidence acute chronic GVHD well relapse-free survival , overall survival toxicity . Correlatives perform evaluate effect 5-aza maintenance immune system . Subjects must transplant candidate MDS high risk characteristic AML . Subjects consent , screen , transplant . Those show complete response active GVHD transplant proceed maintenance 5-aza . Bone marrow biopsy perform response assessment transplant well every three cycle ( 1 cycle=28 day ) treatment . Dosing start 32mg/m2 increase every 2 cycle without serious adverse event ( SAE ) , reduce per toxicity 12 cycle .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Age≥18 MDS highrisk AML , morphologically confirm base World Health Organization criterion ( see definition highrisk AML ) * , transplant candidate available human leukocyte antigen ( HLA ) match sibling unrelated donor least 8/8 match *Definition highrisk AML : Age≥60 year Age &lt; 60 year follow : Secondary AML Poor risk cytogenetics , include abnormality chromosome 3 , 5 , 7 , trisomy 8 , 11q23 abnormality , ( 6 ; 9 ) , 20q , complex karyotype Fmslike tyrosine kinase 3 ( FLT3 ) mutation Disease status ≥ second complete remission ( CR2 ) time HCT Detectable disease time HCT Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Adequate major organ function , define AST ALT &lt; 2 x upper limit normal , total serum bilirubin &lt; 2 x upper limit normal ( unless due hemolysis Gilbert 's syndrome , upper limit ) , creatinine &lt; 2 x upper limit normal , unless know chronic kidney disease ( creatinine must baseline subject chronic kidney disease ) In agreement use effective barrier method birth control avoid pregnancy study minimum 30 day study treatment , male female patient fertile Uncontrolled , lifethreatening infection respond antimicrobial therapy Serum creatinine &gt; 2 x upper limit normal , unless know chronic kidney disease ( creatinine must baseline subject chronic kidney disease ) , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin &gt; 2x upper limit normal History psychiatric disorder may compromise compliance protocol allow appropriate inform consent Patient may receive antineoplastic agent Pregnancy Concurrent use investigational agent clinical trial Prior allogeneic stem cell transplant Known hypersensitivity 5azacytidine * Prior treatment 5azacytidine allow Posttransplant eligibility exclusion criterion Patients meet follow posttransplant eligibility criterion initiate treatment : In complete response ( include complete remission incomplete blood count recovery marrow complete response ) bone marrow biopsy response assessment HCT ( typically day +30 ) Patient within 30100 day HCT Absolute neutrophil count ( ANC ) ≥ 1000/µL , platelet count ≥ 20,000/µL ECOG performance status 02 Adequate major organ function , define AST ALT &lt; 2 x upper limit normal , total serum bilirubin &lt; 2 x upper limit normal ( unless due hemolysis Gilbert 's syndrome , upper limit ) , creatinine &lt; 2 x upper limit normal unless know chronic kidney disease ( creatinine must baseline subject chronic kidney disease ) In agreement use effective barrier method birth control avoid pregnancy study minimum 30 day study treatment , male female patient fertile Patients may follow posttransplant exclusion criterion : Active grade IIIV acute GVHD , example require treatment steroid dose equivalent prednisone 1mg/kg daily high Uncontrolled , lifethreatening infection respond antimicrobial therapy Serum creatinine &gt; 2 x upper limit normal unless know chronic kidney disease ( creatinine must baseline subject chronic kidney disease ) , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin &gt; 2x upper limit normal History psychiatric disorder may compromise compliance protocol allow appropriate inform consent Pregnancy Concurrent use investigational agent clinical trial Known hypersensitivity 5azacytidine * Prior treatment 5azacytidine allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Acute Myeloid Leukemia ( AML )</keyword>
	<keyword>Myelodysplastic Syndrome ( MDS )</keyword>
	<keyword>allogeneic</keyword>
	<keyword>5-azacytidine ( 5-aza )</keyword>
	<keyword>hematopoietic</keyword>
	<keyword>transplantation</keyword>
	<keyword>transplant</keyword>
	<keyword>graft-versus-tumor</keyword>
	<keyword>graft-versus-host disease ( GVHD )</keyword>
	<keyword>epigenetic</keyword>
	<keyword>maintenance</keyword>
	<keyword>hypomethylation</keyword>
	<keyword>relapse</keyword>
</DOC>